
TLX Stock Forecast & Price Target
TLX Analyst Ratings
Bulls say
Telix Pharmaceuticals is a leading radiopharmaceutical company with a strong pipeline and a proven track record of success in developing and commercializing radiopharmaceutical treatments for cancer. With FDA alignment on the design of its Phase 3 ProstACT Global study and encouraging data from its Phase 1 trial, Telix is poised for continued growth and potential to become the standard of care for prostate cancer. With its differentiated biodistribution, favorable dosimetry profile, and convenient dosing regimen, Telix's leading candidate TLX591 has the potential to replace Pluvicto as the standard treatment for prostate cancer, making it a promising investment opportunity.
Bears say
Telix Pharmaceuticals is currently experiencing a low customer demand for its lead product Illuccix, and it faces potential delays in regulatory approvals and clinical trials for its pipeline products TLX591/592, TLX250, TLX101, and TLX66 which make up a significant portion of its revenue forecast. These risks, coupled with the company's high valuation of 8x multiple to 2031-2032 estimated sales and 5x multiple to 2025 estimated sales, make it a risky investment with limited potential for growth in the near future.
This aggregate rating is based on analysts' research of Telix Pharmaceuticals Ltd and is not a guaranteed prediction by Public.com or investment advice.
TLX Analyst Forecast & Price Prediction
Start investing in TLX
Order type
Buy in
Order amount
Est. shares
0 shares